19673-34-8

Basic information

• Product Name: 1-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-1-benzazepine
• CAS NO: 19673-34-8
• Molecular Formula: C₁₇H₁₇NO₂S
• Molecular Weight: 299.3874
• Mol File: 19673-34-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 455.6°C at 760 mmHg
• Flash Point: 229.4°C
• Density: 1.237g/cm³
• Vapor Pressure: 1.73E-08mmHg at 25°C
• Refractive Index: 1.621
• CAS DataBase Reference: 1-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-1-benzazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-1-benzazepine(19673-34-8)
• EPA Substance Registry System: 1-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-1-benzazepine(19673-34-8)

Safety Data

• Hazardous Substances Data: 19673-34-8(Hazardous Substances Data)

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.

Explanation

The chemical structure describes the arrangement of atoms and the type of chemical bonds between them.

Explanation

This property refers to the compound's ability to activate dopamine receptors, which can have various effects on the nervous system.

Explanation

Due to its pharmacological properties, the compound may be useful in the development of treatments for various neurological and psychiatric conditions.

Explanation

The compound's structure and properties make it a subject of interest for researchers in the fields of medicine and pharmaceuticals, as it may lead to the development of new therapeutic agents.

Explanation

Additional research is needed to fully understand the compound's therapeutic potential and to determine its efficacy and safety in treating specific conditions.

Chemical structure

Benzazepine derivative with a sulfonyl group attached to a 4-methylphenyl ring

Pharmacological properties

Dopamine receptor agonist

Potential use

Treating neurological and psychiatric disorders

Research interest

Medicinal and pharmaceutical research

Further study

Potential therapeutic effects

Upstream product

• 19673-33-7 5-hydroxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 

Downstream Products

• 193686-96-3 (4R,5S)-4,5-dihydroxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 193686-94-1 (4S,5R)-4,5-dihydroxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 193686-95-2 acetic acid 5-hydroxy-1-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-4-yl ester 
• 294196-16-0 (4S,5R)-4,5-dimethylmethylenedioxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 294196-70-6 (4R,5S)-4,5-dimethylmethylenedioxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 294196-28-4 (4S,5R)-4-hydroxy-5-methoxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 

Relevant articles and documents

Enantioselective synthesis of the metabolites of vasopressin V2 receptor antagonist OPC-31260 via lipase-catalyzed transesterification

The optical isomers of 5-dimethylamino-1-[4-(2- methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-31260, 1) and its metabolites (2, 3, 4, 5 and 6) were enantioselectively synthesized. The chiral acetate 8b and alcohol 7a were prepared via the resolution of the racemic alcohol (±)-7 using the lipase-mediated transesterification in vinyl acetate. The compounds 8b and 7a were converted to the hydroxy metabolites (2a and 2b), the methylamine metabolites (3a and 3b), the dimethylamines (1a and 1b), and the amine metabolites (4a and 4b) in several steps while maintaining their absolute configurations. The 4,5-diol metabolites (5a, 5b, 6a and 6b) were synthesized from the key intermediates obtained by the lipase-catalyzed transesterification. (C) 2000 Elsevier Science Ltd.